Christopher R. Moore

Christopher R. Moore

Partner
Silicon Valley

Chris Moore's practice primarily focuses on public and private company merger and acquisition transactions and activist defense. Chris has significant experience in both cross-border and domestic transactions, as well as carve-outs and LBOs. He also advises companies and their boards of directors on takeover defense and governance matters.

Chris has advised a broad range of public and private clients across many industries, with a focus on the technology and life sciences sectors. He was recognized for his transactional work in the technology industry by The Legal 500 U.S. in 2018, and he was one of only six mergers and acquisitions lawyers recognized by Law360 as a Rising Star in 2018. He also serves on the Thomson Reuters Practical Law Corporate Advisory Board.

Awards and recognitions

2018

Mergers & Acquisitions, Rising Star
Law360

2018

Media, Technology, and Telecoms: Technology: Transactions
Legal 500 US

2018

Media, Technology, and Telecoms: Telecoms and Broadcast: Transactional
Legal 500 US

Education and admissions

Education

J.D., University of California, Los Angeles, School of Law, 2008

B.A., University of California, Los Angeles, cum laude, 2004

Memberships

Member, Working Group for the ABA 2017 Strategic Buyer/Public Target M&A Deal Points Study

Review Team Member, ABA M&A Carveout Transactions Deal Points Study

Bar admissions and qualifications

California

New York

Representative experience

Walmart in its US$16bn acquisition of a majority stake in Flipkart.

Marvell Technology Group in its US$6bn acquisition of Cavium.

Dialog Semiconductor in its acquisition of Silego Technology.

Synopsys in its acquisitions of Black Duck Software, Protecode, Gold Standard Simulations, Cigital, and Codiscope.*

Atlassian in its acquisitions of OpsGenie and AgileCraft.

Sabre in its pending acquisition of Farelogix.

zulily in its US$2.4bn sale to Liberty Interactive Corporation.*

Eli Lilly in its US$960m acquisition of CoLucid Pharmaceuticals.*

XenoPort in its US$446.6m sale to Arbor Pharmaceuticals.*

*Matter handled prior to joining Hogan Lovells.

Loading data